254 related articles for article (PubMed ID: 30556643)
1. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Oria VO; Lopatta P; Schmitz T; Preca BT; Nyström A; Conrad C; Bartsch JW; Kulemann B; Hoeppner J; Maurer J; Bronsert P; Schilling O
Mol Oncol; 2019 Feb; 13(2):456-479. PubMed ID: 30556643
[TBL] [Abstract][Full Text] [Related]
2. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
3. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
5. The pleiotropic roles of ADAM9 in the biology of solid tumors.
Oria VO; Lopatta P; Schilling O
Cell Mol Life Sci; 2018 Jul; 75(13):2291-2301. PubMed ID: 29550974
[TBL] [Abstract][Full Text] [Related]
6. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma.
Dallas NA; Gray MJ; Xia L; Fan F; van Buren G; Gaur P; Samuel S; Lim SJ; Arumugam T; Ramachandran V; Wang H; Ellis LM
Clin Cancer Res; 2008 Dec; 14(24):8052-60. PubMed ID: 19088020
[TBL] [Abstract][Full Text] [Related]
7. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
Kossmann CM; Annereau M; Thomas-Schoemann A; Nicco-Overney C; Chéreau C; Batteux F; Alexandre J; Lemare F
Tumour Biol; 2017 Jul; 39(7):1010428317716077. PubMed ID: 28675123
[TBL] [Abstract][Full Text] [Related]
9. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
Hamada S; Satoh K; Fujibuchi W; Hirota M; Kanno A; Unno J; Masamune A; Kikuta K; Kume K; Shimosegawa T
Mol Cancer Res; 2012 Jan; 10(1):3-10. PubMed ID: 22064652
[TBL] [Abstract][Full Text] [Related]
10. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells.
Ochi N; Tanasanvimon S; Matsuo Y; Tong Z; Sung B; Aggarwal BB; Sinnett-Smith J; Rozengurt E; Guha S
J Cell Physiol; 2011 Apr; 226(4):1074-81. PubMed ID: 20857418
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S
Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542
[TBL] [Abstract][Full Text] [Related]
13. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin α
Kuo TC; Wu MH; Yang SH; Chen ST; Hsu TW; Jhuang JY; Liao YY; Tien YW; Huang MC
Oncogene; 2021 Feb; 40(7):1242-1254. PubMed ID: 33420364
[TBL] [Abstract][Full Text] [Related]
14. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma.
Yang J; Dong Z; Ren A; Fu G; Zhang K; Li C; Wang X; Cui H
J Cell Mol Med; 2020 Apr; 24(7):4245-4260. PubMed ID: 32141702
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
17. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
Grützmann R; Lüttges J; Sipos B; Ammerpohl O; Dobrowolski F; Alldinger I; Kersting S; Ockert D; Koch R; Kalthoff H; Schackert HK; Saeger HD; Klöppel G; Pilarsky C
Br J Cancer; 2004 Mar; 90(5):1053-8. PubMed ID: 14997207
[TBL] [Abstract][Full Text] [Related]
18. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Jian Z; Cheng T; Zhang Z; Raulefs S; Shi K; Steiger K; Maeritz N; Kleigrewe K; Hofmann T; Benitz S; Bruns P; Lamp D; Jastroch M; Akkan J; Jäger C; Huang P; Nie S; Shen S; Zou X; Ceyhan GO; Michalski CW; Friess H; Kleeff J; Kong B
Cell Mol Gastroenterol Hepatol; 2018; 6(4):429-449. PubMed ID: 30258965
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
20. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
[No Abstract] [Full Text] [Related]
[Next] [New Search]
